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Introduction
In type 1 or type 2 diabetes mellitus, an absolute or relative defi-
ciency of functional pancreatic β cells underlies disease pathogen-
esis. Thus, investigations are focused on identifying native sig-
naling pathways governing human pancreatic β cell proliferation, 
with the goal of expanding functional β cell mass. Islet β cells pro-
liferate in neonatal humans and rodents, but the proliferation rate 
declines thereafter, and reaches its nadir by puberty (1–5). During 
postnatal β cell growth, studies in rodents suggest that hallmark 
β cell functions such as glucose sensing and insulin secretion 
mature (6–10). The mechanisms controlling age-dependent β 
cell proliferation and maturation are being intensely investigated, 
since deciphering these could accelerate development of β cell 
expansion strategies (3, 4, 8, 10–13).
Recent studies have identified age-dependent intrinsic and 
extrinsic regulators in mice and humans that influence or lim-
it islet β cell proliferation. For example, with advancing age, 
increased expression of CDKN2A in β cells, which encodes the 
cell cycle inhibitor p16INK4a, limits β cell regeneration in mice and 
humans (3, 4, 11–13). Native extrinsic signals that regulate β cell 
proliferation include PDGF, prolactin (PRL), and glucagon-like 
peptide 1 (GLP-1). Recent studies have elucidated crucial signal 
transduction elements of these mitogens in β cells (4, 14). For 
example, work on mouse and human islets suggests that the mito-
genic function of PDGF in β cells is age-dependent. While islet 
β cells from neonatal mice and human children express PDGF 
receptors (PDGFRs) and proliferate in response to PDGF-A, β 
cells from adult mice and humans lack PDGFR expression and 
are unresponsive to PDGF stimulation (4). Thus, attenuated 
receptor expression underlies one mechanism of age-dependent 
mitogenic restriction in β cells, underscored by the finding that 
expression of activated PDGFR protein in adult β cells led to β 
cell proliferation (4). PRL-stimulated β cell proliferation is also 
lacking in adult human islets and is accompanied by little or no 
PRL receptor expression in adult β cells (14). However, unlike the 
effects of PDGF signaling, ectopic expression of PRL receptor in 
adult β cells does not restore responsiveness to PRL (14), suggest-
ing that restriction of β cell competence for PRL includes both 
attenuated receptor expression and reduced intracellular signal 
transduction. Thus, mechanisms limiting human β cell respons-
es to PDGF and PRL appear distinct, although both involve age- 
dependent loss of cognate receptor expression.
GLP-1 has a well-established role in stimulating β cell insu-
lin secretion (the incretin effect), in addition to inducing insulin 
biosynthesis, and regulating β cell apoptosis (15–17). GLP-1 and its 
analogs have been previously reported to induce mouse β cell pro-
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22) are in conflict about the ability of GLP-1R agonists to stimu-
late human islet cell proliferation, possibly due to different in vitro 
treatments and assays used. Maintenance of age-dependent islet 
cell proliferation in our transplant system permitted in vivo studies 
of candidate mitogens such as GLP-1/Ex-4 in a physiological con-
text. We hypothesized that human islet β cells have an age-depen-
dent capacity to respond to Ex-4, and used our transplant system 
to investigate this possibility.
First, we examined whether expression of GLP-1R in human 
β cells was different with age. GLP1R mRNA levels were similar in 
juvenile and adult human islets (Figure 2A), suggesting that human 
β cell GLP-1R expression is not age-dependent. Moreover, in FACS- 
isolated islet cell subsets, GLP1R mRNA was principally expressed 
in β cells and was very low, or not detectable, in α cells (Supplemen-
tal Figure 2, A–C), consistent with prior findings (10, 31–35).
To investigate human islet responses to Ex-4, we infused 
Ex-4 in mice transplanted with human islets from juvenile or 
adult donors (Figure 2B); this infusion established pharmacolog-
ically relevant serum Ex-4 levels (Supplemental Figure 2D and 
ref. 36). As expected, blood glucose levels were reduced by Ex-4 
within 24 hours and remained lower during the subsequent treat-
ment period (Figure 2C and Supplemental Figure 2E). Circulating 
human insulin levels in NSG mice bearing human islets (Figure 2, 
D and E) were greater in mice infused with Ex-4. Moreover, this 
incretin effect was observed in mice with juvenile or adult islets. 
Thus, Ex-4 stimulation of insulin secretion in vivo by human islets 
is age-independent, suggesting that downstream signaling that 
regulates GLP-1–stimulated insulin secretion is similar in human 
juvenile and adult islets.
To investigate proliferative responses to Ex-4, we assessed 
β cell proliferation in transplanted juvenile and adult islets. Ex-4 
stimulated β cell replication, marked by Ki67, in juvenile donor 
samples up to age 9 (Figure 2, F, G, and I), but not in islets from 
older donors (20 years and above; Figure 2, H and I). Unlike what 
was observed in β cells, we did not detect changes of α cell or δ cell 
proliferation in response to Ex-4 in juvenile or adult islets (Sup-
plemental Figure 3, A–C). The lack of Ex-4 mitogenic effect on α 
cells is likely explained by our finding that human α cells did not 
express GLP1R mRNA (Supplemental Figure 2, A–C). Thus, these 
studies revealed age-dependent mitogenic effects of Ex-4 on β 
cells, while the insulin secretion effect was age-independent. This 
suggests that divergent downstream pathways regulate these two 
distinct effects of GLP-1R signaling in human β cells.
Ex-4 stimulates calcineurin/NFAT signaling in juvenile human 
islets. To understand the mechanisms underlying Ex-4 mitogenic 
effects in juvenile human islet grafts, we compared the transcrip-
tomes of Ex-4–treated and control PBS-treated juvenile human islet 
grafts and found that 1,440 genes were differentially expressed 
(Figure 3A). Gene sets associated with signaling pathways govern-
ing cell proliferation and vesicle secretion were among those most-
ly upregulated in Ex-4–infused islet grafts. Gene sets comprising 
the NFAT pathway were at the top of this list (Figure 3B).
A prior study reported that signaling through the calcineurin/
NFAT pathway is critical for juvenile β cell proliferation (26). For 
example, this pathway stimulates expression of multiple β cell 
transcription factors and cell cycle activators, including NFATC1, 
FOXM1, cyclin-dependent kinases (CDKs), and the A-type cyclins 
liferation in an age-dependent manner (18). Prior studies investi-
gating whether GLP-1 or exendin-4 (Ex-4) stimulates human β cell 
proliferation have yielded conflicting results (15, 17–22). Thus, it 
remains unclear whether GLP-1 can stimulate human β cell pro-
liferation. GLP-1 stimulates β cell Ca2+ transients (23, 24) through 
the GLP-1 receptor (GLP-1R), and these are known to activate the 
calcium-dependent calcineurin/nuclear factor of activated T cells 
(NFAT) signaling pathway, a crucial regulator of β cell prolifera-
tion and function in neonatal and adult islets (25–28). However, 
the links between GLP-1R responses and downstream intrinsic 
regulators of human β cell proliferation like calcineurin/NFAT sig-
naling have not yet been established.
To test the hypothesis that human β cell proliferative response 
to the GLP-1 analog Ex-4 is age-dependent, we used an in vivo 
transplantation strategy with human islets from juveniles and 
adults (3, 4, 10, 26). Here we report that Ex-4 stimulates β cell 
proliferation in transplanted juvenile, but not adult, human islets, 
and that this response requires intact calcineurin/NFAT signaling. 
Thus, these studies reveal age-dependent signaling pathways and 
mechanisms that stimulate human β cell proliferation.
Results
Age-dependent human islet cell proliferation profile after transplan-
tation. To investigate the age-dependent proliferative potential 
of human islet cells in vivo, we transplanted juvenile (aged 0.5–9 
years) or adult (20 years of age and older) human islets under the 
renal capsule of NOD.Cg-PrkdcscidIl2rgtm1Wjl/Sz (NSG) mice, an 
immunocompromised strain favorable for xenograft studies (ref. 
29 and Figure 1A). Ki67 immunostaining of juvenile islet grafts 4 
weeks after transplantation revealed a greater number of prolifer-
ating cells in juvenile insulin-positive β cells, glucagon-positive α 
cells, and somatostatin-positive δ cells than engrafted adult islets 
(Figure 1, B, C, F, G, J, and K). Compared with engrafted adult 
islets, juvenile islets had 8-fold more Ki67+ β cells (Figure 1, B–E, 
and Figure 1E, inset). We assessed phospho–histone H3 (pHH3), 
an independent marker of proliferation, and found that the num-
ber of pHH3+ β cells was greater in juvenile islets, confirming pro-
gression into G2 or M phases (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI91761DS1). Thus, the greater proliferation of juvenile human β 
cells continued after transplantation, indicating that age-depen-
dent β cell proliferation is maintained and independent of the 
native pancreatic environment.
We also noted a higher percentage of Ki67+ α cells (Figure 1, 
F–I, and Figure 1I, inset) and Ki67+ δ cells (Figure 1, J–M, and Fig-
ure 1M, inset) in transplanted juvenile islets. To our knowledge, 
age-dependent proliferation of these islet cell subsets in humans 
has not been previously reported. In β and α cells, greater Ki67 
labeling was noted in donors up to 3 years of age (Figure 1, D and 
H), while in δ cells, we observed a lower proliferation rate by that 
age (Figure 1L). Within the limits of our donor sampling size, these 
data suggest that the tempo of declining proliferation with age is 
faster in δ cells than in β or α cells.
Ex-4 signaling promotes proliferation in juvenile β cells. GLP-1 
and GLP-1R agonists, like Ex-4, stimulate insulin secretion (the 
incretin effect, reviewed in refs. 15, 17, 30) and are used in the 
treatment of type 2 diabetes. However, prior studies (15, 17–19, 21, 
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plemental Figure 4, C–F). By contrast, mRNA levels of CDKN2A 
and CDKN2B, which respectively encode the β cell cycle inhibitors 
p16INK4a and p15INK4b, were greater in adult human islets (Supple-
mental Figure 4C and refs. 4, 10, 11, 13).
After Ex-4 treatment, we observed an increase in mRNAs 
encoding NFATC1, FOXM1, CCNA1, and CDK1 in juvenile human 
islet grafts (Figure 3, E–G) but not in adult islet grafts (Supplemental 
Figure 5A), suggesting that calcineurin/NFAT signaling was stimu-
lated by Ex-4 only in juvenile human islets. We also found increased 
mRNAs encoding other possible targets of calcineurin/NFAT sig-
naling (Figure 3, E–G) thought to promote cell proliferation, includ-
(26, 27, 37, 38). To unravel signaling links between Ex-4/GLP-1R 
and calcineurin/NFAT pathways in human islets, we first mea-
sured human islet mRNAs encoding all NFAT members and found 
that NFATC2 and NFATC3 were most abundant (Supplemental 
Figure 4, A and B). In human islets, levels of mRNAs encoding 
NFATC1, NFATC2, and NFATC4, but not NFATC3, declined with 
advancing age (Figure 3C), similar to a prior observation that lev-
els of NFATC transcription factors are lower in older mouse islets 
(26). We also found that important cell cycle regulators (CCNA1, 
CCNA2, CDK1, and CDK4) and key transcription factors such as 
FOXM1 are expressed more highly in juvenile human islets (Sup-
Figure 1. Endocrine cell proliferation is greater in transplanted human juvenile islets than in adult islets. (A) Schematic of experimental design. Grafts 
were removed for analysis 6 weeks after transplantation. (B, C, F, G, J, and K) Images of juvenile (left panels) and adult (right panels) grafts labeled with 
insulin (INS, B and C), glucagon (GLU, F and G), or somatostatin (SOM, J and K) in green; Ki67 in red; DAPI in blue. Insets show proliferating Ki67+ cells. 
Scale bar: 50 μm (bar in K applies to all other images in this figure). (D, E, H, I, L, and M) Quantification of percentage Ki67+ β (D and E), α (H and I), and δ (L 
and M) cells of transplanted grafts from individual juvenile (Juv) and adult donors (n = 2–5 grafts per donor; age shown on x axis). The average number of 
β, α, and δ cells counted in each donor sample was approximately 6,000, 3,000, and 2,000, respectively. Insets are average percentage proliferating cells 
in each age group (β cells: data from D and E; α cells: data from H and I; δ cells: data from L and M). Error bars represent SEM. **P < 0.01; ***P < 0.001. An 
unpaired 2-tailed Student’s t test was used for statistical analysis. See also Supplemental Figure 1.
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islet β cells quantified by Ki67 labeling (Figure 4, A–C). In contrast, 
simultaneous infusion of FK506 with Ex-4 prevented increases of 
β cell NFATC4 nuclear localization and proliferation (Figure 4, 
A–C). In control mice receiving PBS plus saline or PBS plus FK506, 
we did not detect differences in human islet β cell NFATC4 nucle-
ar localization or proliferation (Figure 4, A–C), indicating that bas-
al proliferation in transplanted juvenile human β cells was insen-
sitive to FK506. Furthermore, little apoptosis was observed in 
human islet grafts after either treatment (Figure 4D and Table 1). 
Collectively, these data suggest that calcineurin/NFAT signaling 
is required for Ex-4–stimulated human juvenile islet β cell prolif-
eration. Supporting this view, we observed that increased expres-
sion of calcineurin/NFAT signaling targets induced by Ex-4 was 
reduced to basal levels in human islet grafts recovered from mice 
simultaneously infused with Ex-4 and FK506, including NFATC1, 
NFATC3, NFATC4, FOXM1, CCNA1, and CDK1 (Figure 3, E–G). 
Together, these data demonstrate that calcineurin signaling in 
human juvenile islets is required for β cell proliferation.
ing NFATC3, NFATC4, CDK1 (39–41), and EGR3 (42). However, 
mRNA levels of NFATC2, CDKN2A, CDKN2B, or EZH2, a regulator 
of CDKN2A expression and proliferation in β cells (3, 4), were not 
detectably altered in juvenile islets after Ex-4 infusion. Together 
these data suggest that Ex-4 stimulates calcineurin/NFAT signaling 
and thus enhances expression of key transcriptional and cell cycle 
regulators that promote human juvenile β cell proliferation. These 
studies also reveal that the expression of other calcineurin/NFAT 
factors (e.g., NFATC2) and intrinsic inhibitors of β cell proliferation 
(e.g., CDKN2A) was not changed by Ex-4 exposure.
Ex-4 mitogenic effect on human β cells prevented by the calci-
neurin inhibitor FK506. To test whether the mitogenic effects of 
Ex-4 on juvenile human islets are mediated by calcineurin/NFAT 
signaling activation, we infused Ex-4 in mice engrafted with juve-
nile human islets and simultaneously infused FK506, a potent 
specific calcineurin inhibitor (Figure 3D). In mice coinfused with 
Ex-4 and saline, we observed increased nuclear localization of β 
cell NFATC4, and increased proliferation of transplanted human 
Figure 2. Ex-4 promotes β cell proliferation only in juvenile islets. (A) Both juvenile and adult islets express a similar level of GLP1R mRNA measured 
by qPCR (juvenile: n = 6, 0.5–9 years old; adult: n = 6, 20–60 years old). (B) Experimental design. After a 2-week islet engraftment period, PBS or Ex-4 
was delivered by osmotic pump. The grafts were removed and analyses were performed after 4 weeks of treatment. (C–E) Mouse random glucose (C) and 
human insulin (D and E) in mice with transplanted juvenile (D, n = 3 donors) or adult (E, n = 3 donors) human islets 48 hours after the implantation of 
pumps with PBS or Ex-4 (n = 13–14 samples). (F) Representative images of juvenile grafts labeled with insulin (green), Ki67 (red), and DAPI (blue). Insets 
show proliferating Ki67+ cells. Scale bar: 35 μm. (G and H) Percentage of β cell proliferation in grafts from individual juvenile and adult donors (n = 4–8 
grafts per donor). Insets are average percentage in each age group. (I) Statistical analysis of data sets in G and H. Error bars represent SEM. *P < 0.05;  
**P < 0.01; ***P < 0.001. Unpaired 2-tailed Student’s t test or 1-way ANOVA followed by Newman-Keuls multiple-comparisons test (I) was used for statis-
tical analysis. See also Supplemental Figures 2 and 3.
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proliferation in human juvenile, but not adult, islets. The unre-
sponsiveness to Ex-4 in adult human β cells did not reflect absence 
of GLP-1R expression or signal transduction, since Ex-4 stimu-
lated insulin secretion in both juvenile and adult human β cells. 
We show that this β cell proliferative response to Ex-4 requires 
calcineurin/NFAT signaling and also suggest that β cell mitogen-
ic responses to Ex-4 may be limited in adult islets by calcineurin/
NFAT–independent factors, including potent inhibitors of β cell 
proliferation like the cyclin inhibitor CDKN2A (p16INK4A). Thus, 
this work reveals an age-dependent pathway for β cell proliferation 
in human juvenile islets (Figure 5).
We used transplantation of human juvenile and adult islets 
into immunodeficient NSG mice (44, 45) to investigate mecha-
Discussion
Understanding the basis of declining proliferation observed with 
advancing age in human pancreatic islet β cells (1–3, 5) would 
reveal potential strategies for therapeutic human β cell expansion 
in diabetes. Studies with rodent islets have suggested that GLP-1 
stimulates cell proliferation, but most studies on human islets have 
relied on in vitro assays and reported variable effects of GLP-1 on 
proliferation (21, 22, 43). To test the hypothesis that Ex-4, a GLP-1 
analog, stimulates human islet cell proliferation in an age-depen-
dent fashion, we developed an in vivo engraftment system that 
maintained the proliferative competence of juvenile human islet 
cells and an infrastructure to systematically compare human juve-
nile and adult islets. We found that Ex-4 stimulates human β cell 
Figure 3. Gene expression in human islets and juvenile grafts after treatment with Ex-4 and/or FK506. (A and B) RNA-Seq analysis of PBS- or Ex-4–
treated juvenile grafts (n = 3 grafts per treatment, 6-year-old donor). (A) Number of genes regulated by Ex-4 (≥1.5-fold) in juvenile grafts (Ex-4 vs. 
PBS); 1,115 genes are upregulated and 325 are downregulated by Ex-4 treatment. (B) Signaling pathways upregulated by Ex-4. (C) Genes of the NFATC 
family are expressed more highly in juvenile islets (n = 5 donors, age: 0.5, 1.2, 1.7, 3, and 4 years) than adult (n = 5 donors, age: 29, 43, 50, 53, and 60 
years). The average expression level in juvenile islets is defined as 1.00 for each gene. (D) Schematic of transplantation and treatment with Ex-4 plus 
FK506. Two weeks after transplantation, a pump with PBS or Ex-4 was implanted, and a second pump with saline or FK506 was implanted in the  
last 2 weeks. Grafts were removed at 4 weeks. (E–G) Juvenile graft gene expression measured by qPCR. Ex-4 upregulates genes of the NFAT family  
(E), cell cycle regulators (F), and transcription factors (G), and the effects were diminished by FK506 (n = 5 graft samples per treatment from 0.2- and  
6-year-old donors). The average expression level in PBS+saline–treated islets is defined as 1.00 for each gene. Error bars represent SEM. *P < 0.05,  
**P < 0.01, ***P < 0.001 vs. PBS+saline; †P < 0.05, ††P < 0.01, †††P < 0.001 vs. Ex-4+saline; no significant differences between PBS+FK506 and 
Ex-4+FK506. Unpaired 2-tailed Student’s t test or 1-way ANOVA followed by Newman-Keuls multiple-comparisons test (E–G) was used for analysis  
of statistical significance. See also Supplemental Figures 4 and 5.
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nisms controlling human islet cell proliferation. Compared with 
retrospective studies of cadaveric pancreata or in vitro islet cul-
ture–based assays, this in vivo transplantation strategy afforded 
experimental flexibility, including relatively prolonged observa-
tion times, prospective exposure of islets to sequential or concur-
rent schedules of drugs, and serial measures of insulin secretion in 
response to Ex-4. In our transplantation model, the maintenance 
of greater levels of β cell proliferation after transplantation indi-
cates that the proliferation resulted from intrinsic human islet cell 
signals, and was not dependent on the pancreatic environment or 
circulating human factors.
Recent studies suggest that insulin secretion by human islets 
may mature in an age-dependent manner (10), similar to findings 
in rodents (6–9). Using our transplant-based system, however, we 
found that Ex-4 stimulated insulin secretion similarly in both juve-
nile and adult islet grafts, consistent with similar levels of GLP-
1R expression in these islets. By contrast, Ex-4 stimulated β cell 
proliferation only in islets from juvenile donors. This suggests that 
age-dependent factors in adult β cells may suppress proliferation 
or that adult β cells lack factors mediating the proliferative effect 
of Ex-4/GLP-1R signaling, without affecting the incretin effects 
of this signaling pathway (reviewed in ref. 46). These findings are 
also supported by studies here (Figure 2A) and elsewhere (10, 33) 
revealing that GLP1R expression did not detectably change with 
age in human islet β cells. An additional finding from our work is 
that human α cell and δ cell proliferation also appears to decline 
with age, corroborating a recent mass cytometry–based study (47). 
However, unlike in juvenile human β cells, Ex-4 did not stimulate 
proliferation of these other islet cell subsets. This is consistent 
with findings here and from prior studies that GLP1R expression 
in human islet cells is restricted to β cells (Supplemental Figure 2, 
A–C, and refs. 10, 31–35). The circulating Ex-4 level in our system 
(~4 ng/ml) was much higher than the basal plasma GLP-1 level in 
mice (48, 49) or healthy humans (50) but close to the therapeu-
tic concentration target for GLP-1R agonists in clinical use (36). 
The duration of Ex-4 infusion in our study was shorter (28 days) 
Figure 4. Calcineurin/NFAT signaling medi-
ates the mitogenic effect of Ex-4 in juvenile 
β cells. (A) Ex-4 stimulated NFAT transloca-
tion. Insulin (green), NFATC4 (NFAT3) (red), 
DAPI (blue). Scale bar: 15 μm (applies to the 
other images in A). Arrows point to NFATC4+ 
β cells, and insets show NFATC4+ β cells. (B) 
Representative images of β cell proliferation in 
juvenile grafts. Insulin (green), Ki67 (red), DAPI 
(blue). Arrows point to proliferating Ki67+ cells 
(also showed in insets). Scale bar: 35 μm. (C) 
FK506 blocked the β cell proliferation stimu-
lated by Ex-4 in juvenile grafts (n = 4 donors, 
0.2, 1.8, 6, and 9 years old). See also Supple-
mental Figure 6. (D) Representative images of 
TUNEL assay including positive control. Insulin 
(green), TUNEL (red), DAPI (blue). Scale bar: 
50 μm (applies to all images in D). See Table 
1 for the quantification of TUNEL+ β cells in 
PBS+saline–treated, Ex-4+saline–treated, 
PBS+FK506–treated, and Ex-4+FK506–treated 
graft samples from 3 juvenile donors. Error 
bars represent SEM. **P < 0.01. Unpaired 
2-tailed Student’s t test or 1-way ANOVA 
followed by Newman-Keuls multiple-compar-
isons test (C) was used for statistical analysis. 
See also Supplemental Figure 6.
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in comparison with a recent study (16) in which continuous expo-
sure (>250 days) of transplanted islets to the GLP-1R agonist lira-
glutide was found to impair β cell function. Our findings raise the 
possibility that relatively brief exposure to pharmacological levels 
of Ex-4 may be sufficient to stimulate human β cell proliferation, 
and should motivate further studies of Ex-4 dosing and schedule 
effects on β cell growth and function.
Another principal finding here is that Ex-4 effects on human 
β cell proliferation and gene expression require calcineurin/
NFAT signaling. Calcineurin/NFAT signaling is a calcium-respon-
sive pathway required for postnatal β cell expansion in mice and 
humans (26, 27, 51). Prior observations that Ex-4/GLP-1R signal-
ing may provoke Ca2+ transients in β cells (19, 23, 24, 52) suggested 
a connection between GLP-1R and calcineurin/NFAT signaling 
pathways. Our findings here provide direct evidence for stimu-
lation of calcineurin/NFAT signaling by Ex-4 in juvenile human 
islets. FK506 is a potent calcineurin inhibitor used in multiple 
clinical settings, and a role for calcineurin/NFAT in human β cell 
function has also been inferred from the striking observation that 
10%–30% of patients requiring immunosuppression with FK506 
develop diabetes mellitus (28). Here we showed that infusion of 
FK506 eliminated the increased juvenile β cell proliferation and 
gene expression alteration evoked by Ex-4. Together, these find-
ings suggest that the calcineurin/NFAT signaling pathway is cru-
cial for mediating the mitogenic effect of GLP-1R in human juve-
nile β cells. In addition to NFAT, calcineurin signaling regulates 
other factors, including CTRC2, RCAN1, and IRS2 (53–55). Our 
study did not detect an effect of Ex-4 or FK506 on the transcript 
levels of these factors (Supplemental Figure 5). However, we can-
not exclude roles of these or additional factors in the Ex-4 effects 
we observed in human β cells.
Age-dependent decline 
in human β cell responsive-
ness to mitogens was found 
previously to reflect loss of 
mitogen receptor expres-
sion in β cells. For example, 
age-dependent reduction of 
receptors for PDGF and PRL 
in human β cells has been 
noted (4, 14). Similarly to 
PDGFR, GLP-1R signal trans-
duction can stimulate Ca2+ 
transients to activate NFATC transcription factors (47). Thus, we 
speculate that PDGFR and GLP-1R may signal in parallel to reg-
ulate β cell proliferation, a possibility requiring further studies. In 
contrast to age-dependent loss of PDGFR expression and signal-
ing competence observed previously (4), our current work indicates 
that loss of mitogenic responses by adult human β cells to Ex-4 is 
not the result of reduced GLP-1R expression (Figure 2A) or failure 
to activate GLP-1R signaling in cells (Figures 2, C–E). Instead, other 
age-dependent mechanisms constraining β cell proliferation appear 
to limit adult β cell responses to Ex-4. For example, expression of 
intrinsic β cell growth regulators like CDKN2A, CDKN2B, NFATC2, 
and EZH2 (3, 4, 12, 56) was not detectably affected by Ex-4 expo-
sure, suggesting a cell-autonomous basis for age-dependent 
mitogenic responses by human islets to Ex-4. Thus, findings here 
provide motivation for future investigations aiming to rejuvenate 
human adult β cell mitogenic responses to GLP-1 agonists.
In summary, use of a system for investigating age-dependent 
phenotypes in human pancreatic islets revealed that human β cell 
mitogenic responses to GLP-1 are age-dependent and require 
intact calcineurin/NFAT signal transduction. Identification of 
direct and indirect targets of calcineurin/NFAT activation in 
human islet cells could suggest steps for achieving therapeutic 
aims like functional β cell expansion.
Table 1. Quantification of TUNEL+ β cells
Donor age 1.8 yr 6 yr 9 yr
Total β cells TUNEL+ β cells Total β cells TUNEL+ β cells Total β cells TUNEL+ β cells
PBS + saline 2,400 1 4,789 1 1,056 0
Ex-4 + saline 2,458 0 4,610 0 1,489 0
PBS + FK506 401 0 2,264 0 679 0
Ex-4 + FK506 986 0 4,980 0 819 0
 
Figure 5. Model of GLP-1 mitogenic effect mediated by calcineurin/NFAT 
signaling in juvenile human cells. GLP-1 (or Ex-4) binds and activates GLP-
1R, which increases intracellular calcium concentration (56), Ca2+-sensitive 
phosphatase, and calcineurin (Cn). Calcineurin dephosphorylates NFATc 
factors to expose their nuclear localization sequences, which triggers rapid 
entry into the nucleus. In the nucleus, NFATc proteins assemble on DNA 
with partner proteins (termed NFATn) to activate transcription of target 
genes, including cell cycle activators (e.g., cyclins, CDKs) and prolifera-
tion-promoting transcription factors (TFs) such as FOXM1, which are all 
produced at a low level in adult islets. GLP-1/calcineurin/NFAT signaling 
does not appear to regulate the expression of age-associated cell cycle 
inhibitors such as CDKN2A (normally very low level in juvenile islets or its 
repressor EZH2 in juvenile human β cells, which may explain the absence 
of proliferative response to GLP-1 or Ex-4 in adult islets.
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RNA-Seq library preparation, sequencing, and data normalization. 
The PolyA-enriched RNA sequencing library was prepared as pre-
viously described (62). Paired-end sequencing (100 million 100-bp 
paired-end reads) was performed on an Illumina HiSeq2500 sequenc-
er (Illumina Inc.). The quality checks on raw sequence data for each 
sample were performed using FastQC (Babraham Bioinformatics). 
Raw reads were mapped to the reference hg19 using TopHat version 
2.0. The alignment metrics of the mapped reads were estimated using 
SAMtools. Aligned reads were imported to the commercial data anal-
ysis platform AvadisNGS (Strand Scientifics). Samples were grouped 
and transcript abundance was quantified for this final read list using 
trimmed means of M-values (TMM) as the normalization method 
(63). RNA sequencing data have been deposited in the NCBI’s Gene 
Expression Omnibus (GEO) with ID code GSE100660.
Statistics. Statistical significance of differences was determined by 
2-tailed Student’s t test or 1-way ANOVA followed by Newman-Keuls 
multiple-comparisons tests. A P value less than 0.05 was considered 
statistically significant. Values represent mean ± SEM. In RNA-Seq 
analysis, differential expression of genes was calculated on the basis 
of fold changes (using the default cutoff ≥ ±1.5) observed in compari-
sons between defined conditions, and the P value of the differentially 
expressed gene list was estimated by ANOVA using Benjamini-Hoch-
berg corrections of 0.05 for FDR. Differentially expressed genes were 
used for the functional pathway analysis using Ingenuity Pathway 
Analysis (IPA; Qiagen Inc.).
Study approval. All human islet studies were approved by the Van-
derbilt Institutional Review Board. All animal studies were approved 
by the Vanderbilt Institutional Animal Care and Use Committee.
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Methods
Human islet procurement, quality assessment, and transplantation. 
Deidentified human pancreatic islets were obtained from previous-
ly healthy, nondiabetic organ donors. Islets from 14 juvenile donors 
(ages 0.2, 0.5, 1.2, 1.7, 1.8, 3, 3, 4, 5, 5, 6, 7, 9, and 9 years) were pro-
cured through the National Disease Research Interchange (http://
ndriresource.org) and the International Institute for the Advance-
ment of Medicine (http://www.iiam.org). Juvenile islets were isolated 
at the Institute of Cellular Therapeutics of the Allegheny Health Net-
work (Pittsburgh, Pennsylvania, USA) as previously described (3, 4, 
26). Islets from 12 adult donors (ages 20, 21, 29, 30, 40, 43, 43, 48, 49, 
53, 60, and 60 years, BMI ranges 24.1–29.6) were obtained from the 
Integrated Islet Distribution Program (http://iidp.coh.org). Islet func-
tion (i.e., glucose-induced insulin secretion) was assessed by islet 
perifusion assay on the day of arrival, as previously described (57, 58). 
Each human islet preparation was handpicked on the day of arrival 
for gene expression studies (57). Male NOD.Cg-PrkdcscidIl2rgtm1Wjl/Sz 
(NSG) mice (44, 45), aged 12–18 weeks, were used for transplantation. 
Human islets were transplanted under the kidney capsule as previ-
ously described (29, 59, 60).
Ex-4 and FK506 administration. Two weeks after human islet trans-
plantation, Ex-4 (24 nmol/kg/d; California Peptide Research Inc.) or 1× 
PBS was delivered by micro-osmotic pumps (Alzet 1004) implanted in 
recipient NSG mice (Figure 2B). For FK506 (tacrolimus) experiments, a 
second pump (Alzet 1002) loaded with FK506 (0.25 mg/kg/d; Astellas 
Ireland Co.) or saline was implanted 2 weeks after the Ex-4 pump was 
placed (Figure 4A). Serum Ex-4 levels in recipient mice were measured 
using the Exendin-4 EIA kit (Phoenix Pharmaceuticals Inc.).
Immunohistochemistry of human islet grafts. Recovered human islet 
grafts were fixed in 4% paraformaldehyde in PBS and cryopreserved. 
Five-micrometer-thick frozen sections were cut and stained as previ-
ously described (60). Primary antibodies used were rabbit anti–human 
Ki67 (Abcam, ab15580), guinea pig anti–human insulin (DAKO, 
A0564), mouse anti-glucagon (Abcam, ab10988), goat anti-soma-
tostatin (Santa Cruz Biotechnology, sc7819), and rabbit anti–histone 
H3 (phospho S10) (Abcam, ab5176). Images were obtained using an 
Olympus BX41 fluorescence microscope. Proliferating islet cells 
were quantified by counting of Ki67+ and hormone-positive cells as 
described previously (57, 60, 61). Apoptosis was assessed by TUNEL 
(Millipore, S7165) following the manufacturer’s instructions.
RNA isolation, cDNA synthesis, and quantitative reverse transcrip-
tase PCR. Total RNA was extracted from isolated human islets or 
recovered human islet grafts using an RNAqueous RNA isolation kit 
(Ambion). RNA quality control and quantity assessment (QC/QA) was 
performed using a Bioanalyzer instrument in the Vanderbilt Technol-
ogies for Advanced Genomics (VANTAGE) core laboratory. Only sam-
ples with a 28S/18S ratio greater than 1.2 and an RNA integrity number 
greater than 8.1 were used for subsequent analysis. cDNA was synthe-
sized using a High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, 4368814) according to the manufacturer’s instructions. 
Quantitative PCR (qPCR) was performed using TaqMan assays (Sup-
plemental Table 1) and reagents from Applied Biosystems as previ-
ously described (57). ACTB and TFRC were used as endogenous con-
trols in islet gene measurement, while SYPL1, SV2A, and CHDA were 
used for control genes in graft gene assay. Relative changes in mRNA 
expression were calculated by the comparative ΔCt method using the 
Applied Biosystems StepOne Plus System.
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